EP0793654A1

EP0793654A1 - Antibacterial dibenzimidazole derivatives

Info

Publication number: EP0793654A1
Application number: EP95934584A
Authority: EP
Inventors: Walter Haesler; Yu-Hua Ji; Werner Leupin
Original assignee: F Hoffmann La Roche AG
Current assignee: F Hoffmann La Roche AG
Priority date: 1994-11-17
Filing date: 1995-11-02
Publication date: 1997-09-10
Also published as: BR9509671A; JPH09512831A; BR9509671C1; MX9703634A; FI972090A0; FI972090A; US5824698A; AU3696495A; CA2204639A1; WO1996016042A1

Abstract

The invention concerns novel and known dibenzimidazoles of formula (I), in which R?1 and R2¿ may be the same or different and are C¿6?H4R?3-, C¿6H3(OH)R4 or heterocyclyl, R3 represents hydroxy, amino, lower alkoxy or cyano, and R4 is halogen, lower alkyl or lower alkoxy, and pharmaceutically useful salts of compounds of general formula (I) which have an antibacterial effect, in particular against Staphylococcus, Enterococcus and Heliobacter pylori.

Description

1 -

ANTIBACTERIAL DIBENZIMIDAZOLE DERIVATIVES

The invention relates to dibenzimidazole derivatives. In particular, it relates to 2,2'-bis-substituted 6,6'-dibenziπjidazoles of the general formula

wherein

R ¹ and R ^{2 can be the} same or different and C6H4 ³ -, C6H3 (OH) R - or heterocyclyl,

R ^{3 is} hydroxy, amino, lower alkoxy or cyano and R ^{4 is} halogen, lower alkyl or lower alkoxy, and pharmaceutically acceptable salts of compounds of the general formula I.

These connections are new, with the exception of the

4- [2 '- (4-Hydroxyphenyl) -6,6'-dibenzimidazol-2-yl] phenol, 3- [2' - (3-Hydroxyphenyl) -6,6'-dibenzimidazol-2 -yl] phenols,

4- [2 '- (4-aminophenyl) -6,6'-dibenzimidazol-2-yl] phenylamine and des

4- [2 '- (4-Cyano-phenyl) -6,6'-dibenzimidazol-2-yl] benzonitrile.

The compounds of formula I and their pharmaceutically acceptable salts show very good antibacterial activity, especially against Gram-positive pathogens such as Staphylococcus and Enterococcus faecalis. They also show good activity against Helicobacter pylori.

They are therefore suitable for the prevention and treatment of diseases which are caused by such pathogens.

Symmetrical bis-benzimidazoles have been described in the literature as starting materials for the preparation of polybenzimidazoles (J. Org. Chem., 42, 3485-3491 [1977]). The use of these compounds as therapeutic agents, in particular for the prevention or treatment of bacterial diseases, is new.

The present invention relates to compounds of general formula I and pharmaceutically acceptable salts thereof for use as therapeutic agents, in particular as agents against bacterial pathogens; Medicaments containing one or more compounds of general formula I or pharmaceutically acceptable salts thereof; the use of these compounds in combating or preventing diseases which are caused by bacterial pathogens and in the preparation of medicaments for the indications mentioned; as well as the new compounds of formula I, their pharmaceutically acceptable salts and the preparation of the new compounds and salts.

The term "lower alkyl" used in the present description expediently denotes those having up to 7, preferably up to 4, carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t- Butyl and the like.

Halogen means chlorine, bromine, fluorine or iodine.

The term "lower alkoxy" denotes a lower alkyl radical bonded via an oxygen atom.

For the purposes of the present description, the term "heterocyclyl" means a 5- or 6-membered unsaturated ring having at least one heteroatom such as 0, S or N, for example furyl, pyranyl, thienyl, pyrrolyl or pyridyl. Compounds of the formula I in which R ¹ and R ^{2 are} identical or different and are CβHiR ³ - or C6H3 (OH) R ⁴ -, R ³ and R ^{4 have} the meaning given above are particularly preferred for use as therapeutic active substances and wherein a substituent preferably occupies a 4- or optionally a 3-position on the phenyl ring.

It was found that the antibacterial effect is particularly high when the substituents R ³ or R ⁴ or the hydroxyl group in C6H3 (OH) ⁴ - for R ¹ or R ^{2 are} in the 4-position. Compounds in which a

Hydroxy group is in the 4-position on the phenyl ring. The following compounds are particularly preferred for use as therapeutic agents:

4- [2 '- (4-hyroxyphenyl) -6,6'-dibenzimidazol-2-yl] phenol; 3- [2 '- (3-Hydroxyphenyl) -6,6 ^* -dibenzimidazol-2-yl] phenol;

4- [2 '- (4-Amino-phenyl) -6,6 ^, -dibenzimidazol-2-yl] phenylamine;

2-fluoro-4- [2 '- (3-fluoro-4-hydroxyphenyl) -6,6'-dibenzimidazol-2-yl] phenol;

4- [2 '- (4-Hydroxy-3-methoxyphenyl) -6,6'-dibenzimidazol-2-yl] -2-methoxyphenol;

5- [2 '- (3-Hydroxy-4-methoxyphenyl) -6,6 ^, -dibenzimidazol-2-yl] -2- methoxyphenol;

2,2'-bis (4-methoxyphenyl) -6,6'-dibenzimidazole;

2,2'-bis (4-ethoxyphenyl) -6,6'-dibenzimidazole; 4- [2 '- (4-ethoxyphenyl) -6,6'-dibenzimidazol-2-ylJ phenol;

4- [2 '- (4-Hydroxyphenyl) -6,6'-dibenzimidazol-2-yl] benzonitrile.

According to the invention, the symmetrically substituted compounds of the formula I in which R ¹ and R ^{2 have} the same meaning can be prepared by using the compound of the formula

with an excess of a reactive compound which provides the radical R ¹ or R ² . The asymmetrically substituted compounds of the formula I in which R ¹ and R ² do not have the same meaning can be prepared according to the invention by reacting the compound of the formula II simultaneously with two different reactive compounds which provide the radicals R ¹ and R ² .

Another way of producing symmetrical or asymmetrical compounds of the formula I is to prepare a compound of the formula

wherein R ^{1 has} the meaning given above, with a reactive agent which provides the radicals R ¹ or R ² .

Both the symmetrically substituted compounds and the unsymmetrically substituted compounds of the formula I can, if desired, be converted into a pharmaceutically acceptable salt.

The following can be used, for example, as reactive compounds which are suitable for the preparation of the compounds of the formula I:

3- or 4-hydroxybenzaldehyde, ethyl imide ester of 4-hydroxybenzoic acid,

4-amino-benzaldehyde,

3-fluoro-4-hydroxy-benzaldehyde,

4-hydroxy-3-methyl-benzaldehyde,

4-hydroxy-3-methoxy-benzaldehyde, 4-methoxy-benzaldehyde,

4-ethoxybenzaldehyde,

3-hydroxy-4-methoxy-benzaldehyde,

Ethyl imide ester of furan carboxylic acid,

4-cyano-benzaldehyde.

Other correspondingly substituted aldehydes are also suitable,

Acids, esters, anhydrides, alkylimides or acyl halides (described ben in Chem. Rev. JA, 279-314; The Chemistry of Heterocyclic Compounds, Part I, Vol. 40, pp. 1-286, 1981; Comprehensive Heterocyclic Chemistry, Vol. 5, pp. 457-487).

In the preparation of the symmetrically substituted compounds of the formula I, 3,3'-diamine-benzidine (II) is reacted with a reactive compound which provides the radical R ¹ or R ² .

Appropriately, the procedure is such that the 3,3'-diamine-benzidine is mixed with twice the amount of the reactive derivative in a solvent, e.g. Ethanol is reacted for several hours at the boiling point of the solvent used.

Na2S2θs or nitrobenzene are particularly suitable as additives for the preparation of the compounds of the formula I if aldehydes are used as reactive derivatives. If acids, esters, anhydrides, alkylimides or acyl halides are used, HC1 (J. Chem. Soc, 2393-2399, [1928]), polyphosphoric acid (J. Amer.

Chem. Soc. 7_9_, 427-429 [1957]) or optionally nitrobenzene (Synth. Commun. 0, 955-963 [1990]).

Unsymmetrically substituted dibenzimidazoles can be prepared in a similar manner.

Starting from 3,3'-diamine-benzidine (II), the reaction takes place with two different reactive compounds, for example with two differently substituted aldehydes.

The compound 4- [2 '- (4-ethoxyphenyl) -6,6'-dibenzimidazol-2-yl] phenol is thus obtained, for example, by reacting 3,3'-diaminobenzidine with 4-hydroxybenzaldehyde and 4-ethoxy-benzaldehyde in ethanol and addition of Na2S2θs after stirring for several hours at reflux.

In addition to the asymmetrically substituted dibenzimidazoles, the reaction solution also contains the corresponding symmetrical compounds.

Symmetrically or asymmetrically substituted dibenzimidazole derivatives can also be obtained by using a compound of the formula with an above-mentioned reactive compound which provides the radical Rl or R ² . The implementation is analogous to the process described above.

The pharmaceutically acceptable salts can be prepared according to known

Methods are made. The free bases of the formula I can be converted, for example, into the corresponding salts using the following inorganic or organic acids: hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulfonic acid, p -Toluenesulfonic acid and the like.

Preferred salts are the hydrochlorides derived from the basic compounds of formula I, e.g. with a methanolic HC1 solution.

The starting compounds required for the preparation of the compounds of formula I are known commercial products, e.g. the compound II, or can be easily prepared by methods known per se.

So you can e.g. the compound III by reacting 3-

Amino-3'-nitro-benzidine with a reactive compound which provides the radical R ¹ , for example with 4-hydroxy-benzaldehyde, is obtained by subsequently hydrogenating the nitro group of the isolated intermediate to give the amino group. The hydrogenation is carried out according to methods described in the literature, for example with

Hydrogen ^" or hydrazine in the presence of Raney nickel.

The compound III obtained can then, as described, be reacted with a further compound which provides the radical R ¹ or R ² to give the dibenzimidazoles of the formula I. All reactive compounds required for the preparation of the compound I, which contain the radicals R ¹ or R ² , are known compounds and / or can be prepared in an analogous manner by processes described in the literature.

For example, the ethyl imide ester of 4-hydroxybenzoic acid can be prepared as follows:

4-Hydroxy-benzonitrile is treated several times with dry HCl gas in a solvent mixture, for example in a chloroform-ethanol mixture, at room temperature, the hydrochloride formed being separated off in the meantime. The resulting ester can then be converted to compounds of the formula I without further purification.

As mentioned at the beginning, the substituted 6,6'-dibenzimidazoles of the formula I and their pharmaceutically acceptable salts have extremely valuable pharmacological properties. Their activity against various bacterial strains, especially their very good activity against gram-positive bacteria, is shown in Table 1 (in vitro).

Assessment of antibacterial activity

The minimum inhibitory concentration (MIC) of the substances examined against gram-positive and gram-negative strains was determined using standard agar methods. The compounds were dissolved in a small amount of dimethyl sulfoxide, diluted with water and incorporated in liquefied DST agar at 50 ° C. The agar plates thus produced were used in the experiment immediately afterwards. The test concentrations were between 128 and 0.06 μg ml. The bacterial vaccine solutions were prepared from pre-cultures incubated overnight, diluted and applied to the agar surface using an inoculation device (Denley A400). The plates were incubated at 35 ° C for 20 hours. The MIC was determined as the lowest substance concentration that prevents visible growth. A barely visible cloudiness and that

Growth of less than 5 colonies was neglected. The determinations of the antibacterial activities (Tab. 1) were both for the free bases as well as for the hydrochloride salt of each Connection made. The same values were obtained within the experimental error.

The antibacterial activities against Helicobacter pylori were carried out analogously to the method described above, with the following changes: The compounds were incorporated in Müller-Hinton agar with 5% sheep blood additive. The test concentrations were between 10 and 0.1 μg ml. The preincubation time was 5 days, the incubation time 4 days for H. pylori K 1585 and 7 days for H. pylori PN 81.

TabeDel Antibacterial activity in vitro

The products according to the invention can be used as medicaments, for example in the form of pharmaceutical preparations, which they or their salts are mixed with a pharmaceutical, organic or inorganic inert carrier material suitable for parenteral or enteral application, such as water, gelatin,

Contain gum arabic, milk sugar, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, petroleum jelly, etc. The pharmaceutical preparations can be in solid form, e.g. as tablets, tablets, suppositories, capsules, or in liquid form, e.g. as solutions, suspensions or emulsions.

If necessary, they are sterilized and / or contain auxiliary substances such as preservatives, stabilizers, wetting agents or emulsifiers, salts for changing the osmotic pressure, anesthetics or buffers. The compounds of the formula I and their salts are preferably suitable for parenteral administration and are preferably prepared for this purpose as lyophilisates or dry powder for dilution with conventional agents such as water or isotonic saline.

The dosage of the compounds of general formula I and the pharmaceutically acceptable salts thereof with bases can vary within wide limits and is of course to be adapted to the individual circumstances and the pathogen to be controlled in each individual case.

As mentioned at the outset, medicaments containing a compound of the general formula I or a pharmaceutically acceptable salt thereof, also a subject of the present invention, are also a process for the preparation of such medicaments, which is characterized in that one or more compounds of the general formula I or pharmaceutically acceptable salts thereof and optionally one or more other therapeutically valuable substances in a pharmaceutical dosage form.

The following examples further illustrate the invention. Synthesis of the symmetrically substituted bis-benzimidazoles

Example 1 2-Fluoro-4-r2 ^ 3-fluoro-4-hvdroxv-phenvl) -6.fi'-dihenzimidazole-2-vI1-shsus

Method A

0.43 g (2 mmol) of 3,3'-diamino-benzidine and 0.56 g (4 mml) of 3-fluoro-4-hydroxy-benzaldehyde were dissolved in 50 ml of ethanol and mixed with a solution of 0.38 g ( 2 mmol) Na2S2θs and 5 ml of water were added. The reaction solution was stirred under reflux for 16 hours. Insoluble products were filtered off. By adding 60 ml

The product was precipitated in water, filtered off and treated with 100 ml of hot methanol. The methanolic solution was filtered and a methanolic HCl solution was added to the filtrate. After the solvent had been partially distilled off, the dihydrochloride precipitated out in the form of beige crystals. Yield: 610 mg (58%).

Example 2

2.2 ^, -Dimethyl-6.β'-dibenzimidazol-2.2'-ylen.diphenol

2.14 g (10 mmol) of 3,3'-diaminobenzidine, 2.72 g (20 mmol) of 4-hydroxy-3-methylbenzaldehyde and 1.9 g (10 mmol) of Na2S2θs gave 1.1 g of dihydrochloride in analogy to Method A. Form of colorless crystals.

Yield: 47%.

Example 3

4-r2 '- (4-Hvdroxy-3-methoxy-phenyl) -6.6'-dibenzimidazole-2-vn-2-methoxy-phenol

1.07 g (5 mmol) 3,3'-diamino-benzidine, 1.54 g (10 mmol) 4-hydroxy-

3-methoxybenzaldehyde and 0.95 g (5 mmol) Na2S2θs gave analogously to method A 0.2 g dohydrochloride in the form of beige crystals. Yield: Example 4

5-r2 '- (3-Hvdroxy-4-methoxy-phenvl) -β.fi'-dibenzimidazole-2-vn-2-methoxv-phenol

1.07 g (5 mmol) of 3,3'-diamino-benzidine, 1.54 g (10 mmol) of 3-hydroxy-4-methoxybenzaldehyde and 0.95 g (5 mmol) of Na2S2θs gave analogously

Method A 0.4 g dihydrochloride in the form of beige crystals. Yield: 17%.

Example 5

4-r2 '- (4-Hvdroxv-phenvl) -6.6'-dibenzimidazole-2-vl) phenol

4.29 g (20 mmol) 3,3'-diamino-benzidine, 4.88 g (40 mmol) 4-

Hydroxybenzaldehyde and 3.8 g (20 mmol) Na2S ₂ θs gave analogously

Method A 2.09 g dihydrochloride in the form of beige crystals. Yield: 25%.

Method B

2.14 g (10 mmol) 3, 3'-diamino-benzi di n and 4.05 g (20 mmol) des

Ethyl imido ester hydrochlorides of 4-hydroxybenzoic acid were dissolved in 300 ml of ethanol and refluxed for 2 hours. The reaction solution was then cooled to room temperature. After adding 200 ml of water, a fine white precipitate was formed. The precipitate was filtered off and extracted from a methanolic

HCl solution recrystallized. The dihydrochloride was obtained in the form of beige crystals. Yield: 1.45 g (25%).

Example 6

3-r2'- ⁽ 3-Hvdroxy-phenyl) -6.6'-dibenzimidazol-2-yl1-phenol

1.07 g (5 mmol) of 3,3'-diamino-benzidine, 1.22 g (10 mmol) of 3-hydroxybenzaldehyde and 0.95 g (5 mmol) of Na2S2θs gave 1.2 g of dihydrochloride in analogy to Method A. Shape of beige crystals. Yield: 57%. Example 7

4-r2 '- (4-amino-nhenvl -6.6'-dibenzimidazole-2-vl1-phenvlamine

5.35 g (25 mmol) of 3,3'-diamino-benzidine, 5.55 g (50 mmol) of 4-amino-benzaldehyde and 4.75 g (25 mmol) of Na2S2θs gave 0.35 g of dihydrochloride in analogy to Method A. Shape of beige crystals. Yield: 5%.

Example 8

2.2'-bis- (4-methoxv-phenvl) -β.β'-dibenzimidazole

1.07 g (5 mmol) of 3,3'-diamino-benzidine, 1.36 g (10 mmol) of 4-methoxybenzaldehyde and 0.95 g (5 mmol) of Na2S2θs gave analogously to Method A 0.41 g of dihydrochloride in the form of colorless Crystals. Yield:

18%.

Method C

A mixture of 1.07 g (5 mmol) of 3,3'-diamino-benzidine and 1.49 g (11 mmol) of 4-methoxy-benzaldehyde, dissolved in 50 ml of nitrobenzene, was stirred at 140 ° C. for 24 hours. After cooling to room temperature, the reaction solution was concentrated by vacuum distillation. The residue obtained was purified by chromatography on a Florosil column. CH2CI2 CH3OH (98: 2 - 90:10) was used as eluent. The appropriate fraction was collected to give 1.34 g of 2,2'-bis (4-methoxyphenyl) -6,6'-dibenzimidazole in the form of a beige solid. Yield: 56%.

Example 9

2,2'-bis (4-ethoxv-phenvl) -6.β'-dibenzimidazole

2.14 g (10 mmol) of 3,3'-diamino-benzidine, 3.0 g (20 mmol) of 4-ethoxybenzaldehyde and 1.9 g (10 mmol) of Na2S2θδ gave analogously to Method A.

3.4 g of dihydrochloride in the form of white crystals. Yield: 72%. Example 10

2,2'-difuran-2-yl-6,6'-dihenzimidazole

0.64 g (3 mmol) of 3,3'-diamino-benzidine and 1.05 g (6 mmol) of ethyl imido ester of furan-2-carboxylic acid gave 0.16 g of dihydrochloride in the form of beige crystals in analogy to Method B. Yield 12%.

Synthesis of the asymmetrically substituted bis-benzimidazoles

Example 11

4-r2 '- (4-Ethoxv-phenvl) -6.6'-dibenzimidazol-2-yl1-phenol

3.15 g (15 mmol) of 3,3'-diamino-benzidine, 1.83 g (15 mmol) of 4-hydroxybenzaldehyde and 2.75 g (15 mmol) of 4-ethoxybenzaldehyde were dissolved in 100 ml of ethanol and mixed with 2 85 g (15 mmol) Na2S2θs, dissolved in 20 ml water, added. The reaction mixture was boiled under reflux for 24 hours and then filtered. 100 ml of water was added to the filtrate to precipitate the product. The solid was filtered off and purified by column chromatography (400 g

Silica gel; Methylene chloride: methanol (9: 1) was used as the eluent). The product was recrystallized from methanol. 0.4 g of yellowish crystals of 4- [2 '- (4-ethoxyphenyl) -6,6'-dibenzimidazol-2-yl] phenol were formed. Yield: 6%.

Example 12

4-r2'- ⁽ 4-Hvdroxy-phenyl) -6.6'-dibenzimidazole-2-vn-benzonitrile

4.28 g (20 mmol) of 3,3'-diamino-benzidine, 2.44 g (20 mmol) of 4-hydroxybenzaldehyde and 2.62 g (20 mmol) of 4-cyanobenzaldehyde were dissolved in 500 ml of ethanol and mixed with 3. 8 g (20 mmol) Na2S2θs, dissolved in 100 ml water, added. The reaction mixture was on for 16 hours

Boiled under reflux and then filtered. The product was precipitated by adding 500 ml of water to the filtrate and filtered again. The crude product (6.7 g) was purified by column chromatography (silica gel; methylene chloride: methanol (9: 1) was used as the eluent). The product was out

Recrystallized methanol. 0.8 g of yellowish crystals of 4- [2 '- (4-Hydroxyphenyl) -6,6'-dibenzimidazol-2-yl] benzonitrile. Yield: 10%.

Manufacture of intermediates

Example 13 Ethvl-imido-ester of 4-Hvdroxv-benzoic acid

22.4 g (188 mmol) of 4-hydroxybenzonitrile were dissolved in 200 ml of chloroform and 50 ml of ethanol. With stirring and cooling (the temperature of the solution should never exceed 20 ° C), dry HCl gas was introduced until saturation. The hydrochloride precipitated out as a white crystalline precipitate. After 2 hours the

The reaction solution is filtered and the crude product is suspended in 150 ml of ethanol. With stirring and cooling (the temperature of the solution should be approx. 20 ° C), dry HCl gas was again introduced into the solution until saturation. The white crystals were filtered off and used without further purification. Yield:

18.0 g. Mp 207-209 ° C (dec.).

Example 14

Ethvl-imido-ester of furan-2-carboxylic acid

The synthesis was carried out in analogy to Example 13.

9.3 g (0.2 mol) of 2-cyano-furan gave 4.8 g of colorless crystals.

Yield: 27% of the corresponding hydrochloride of the imido ester. M.p. 117-119 ° C.

Table 2 Characteristic of the compounds of Examples 1-12

Example No. iH-NMRSt »el ren * Rf- m.p. free base; Values ** (° C) hydrochloride

4. 6.94 (d, 4H); 7.52 (dd, 2H); 7.63 (dd, 2H); > 260 7.78 (s, 2H), 8.04 (d, 4H). 4 (2HC1) 7.11 (d, 4H); 7.89 (s, 4H); 8.01 (s, 2H); 0.09 (9: 1) 8.26 (d, 4H) 0.77 (3: 1)

5 6.92 (dd, 2H); 7.37 (t. 2H); 7.55 -7.70 (m, 8H); > 260 7.84 (s, 2H) 5 (2HC1) 7.19 (dd, 2H); 7.53 (t. 2H); 7.73 (s. 2H); 7.82 0.29 (9: 1) (d, 2H); 7.94 (m, 4H); 8.07 (s, 2H)

6 6.74 (d, 4H); 7.68 (m, 4H); 7.86 (s. 2H); > 260 7.91 (d, 4H)

6 (2HC1) 6.80 (d, 4H); 7.84 (s, 4H); 7.95 (s. 2H); 0.09 (9: 1) 8.09 (d, 4H) 0.63 (3: 1)

17.12 (t, 2H); 7.54 (d. 2H); 7.65 (d. 2H); 7.81> 260 (s, 2H); 7.88 (dd, 2H); 7.96 (dd, 2H) 2 (2HC1) 7.29 (t, 2H); 7.88 (s, 4H); 8.00 (s, 2H); 8.09 0.15 (9: 1) (dd, 2H); 8.27 (dd, 2H)

2 2.24 (s, 6H); 6.94 (d, 2H); 7.50 (dd, 2H); 7.61> 260 (dd, 2H), 7.77 (s, 2H); 7.86 (dd, 2H); 7.95 (s, 2H)

2 (2HC1) 2.25 (s, 6H); 7.12 (d, 2H); 7.86 (s, 4H); 7.97 0.0 (0: 1) (s, 2H); 8.11 (dd, 2H); 8.16 (d, 2H) 0.80 (3: 1)

3 3.91 (s, 6H); 6.94 (d, 2H); 7.52 (dd, 2H); 7.6-7.7> 260 (m, 4H); 7.78 (d, 4H) 3 (2HC1) 3.96 (s, 6H); 7.10 (d, 1H); 7.85-7.92 (m, 6H); 8.0: 0.2 (9: 1) (s, 2H); 8.09 (d, 2H)

7 3.87 (s, 6H); 7.11 (d, 2H); 7.50-7.70 (m.lOH)> 260 7 (2HC1) 3.93 (s, 6H); 7.28 (d. 2H); 7.72 (s. 2H); 7.82 0.20 (9: 1) (d, 2H); 7.86 (s, 4H); 7.99 (s, 2H)

8 3.86 (s, 6H); 7.13 (d. 4H); 7.53 (d. 2H); 7.66> 260 (d, 2H); 7.82 (s, 2H); 8.16 (d, 4H) 8 (2HC1) 3.92 (s, 6H); 7.30 (d, 4H); 7.88 (q, 4H); 8.00 0.59 (9: 1) (s, 2H); 8.37 (d, 4H)

9 1.38 (t, 6H); 4.13 (q, 4H); 7.12 (d, 4H); 7.55> 260 (dd, 2H); 7.66 (d. 2H); 7.82 (s, 2H); 8.14 (d, 4H) 9 (2HC1) 1.39 (t, 6H); 4.18 (q, 4H); 7.25 (d. 4H); 7.84 0.41 (9: 1) (q, 4H); 7.97 (s, 2H); 8.32 (d, 4H) 10 6.80 (d, 2H); 7.37 (d. 2H); 7.62 (d. 2H); 7.70> 260 (d, 2H); 7.85 (s. 2H); 8.04 (s, 2H) 10 (2HC1) 6.95 (dd, 2H); 7.79 (d. 2H); 7.85 (s. 4H); 7.98 0.45 (9: 1) (s, 2H); 8.26 (dd, 2H)

11 1.38 (t, 3H); 4.17 (q, 2H); 7.06 (d, 2H); 7.20> 260 (d, 2H); 7.70 - 7.70 (m, 4H); 7.94 (s, 2H); 8.18 (d. 2H); 8.25 (d, 2H) 11 (2HC1) 1.39 (t, 3H); 4.19 (q, 2H); 7.11 (d, 2H); 7.27 0.25 (9: 1) (d, 2H); 7.88 (s, 4H); 8.00 (s, 2H); 8.26 (d. 2H); 8.35 (d. 2H)

12 6.94 (d, 2H); 7.54 (dd, 1H); 7.62 (t, 2H); 7.75> 260 (broad s, 1H); 7.82 (s, 2H); 8.04 (d, 2H); 8.06 (d, 2H); 8.38 (d, 2H) 12 (2HC1) 7.12 (d, 2H); 7.74 (d, 1H); 7.85 (d.IH); 7.90 0.22 (9: 1) (s, 2H); 8.01 (s, 2H); 8.12 (d. 2H); 8.24 (d. 2H); 8.45 (d, 2H)

* -Η NMR spectra were recorded at 250 MHz in DMSO-dβ at a temperature of 298 ° k. The concentration of the compounds was 2 mmol. The chemical shifts δ (± 0.02 ppm) were measured relative to δ (TMS) = 0.0 ppm; s = singlet, d = doublet, t = triplet, q = quartet, m = multiple «.

** The Rf values were measured on a Si-coated glass plate (Merck). A mixture of 9 parts by volume of methylene chloride and 1 part of methanol (9: 1) or a solution of 3 parts by volume of methylene chloride and 1 part of methanol (3: 1) was used as the eluent.

Example A

Ampoules for intramuscular administration are produced in the usual way:

A lyophilisate of 1 g of 4- [2 '- (4-hydroxyphenyl) -6,6'-dibenzimidazol-2-yl] phenol hydrochloride (1: 2) is prepared in the usual manner and

Made way and filled into an ampoule. Before administration, the lyophilisate is treated with 2.5 ml of 2% lidocaine hydrochloride solution.

Example B Tablets of the following composition are produced in the usual way: mg / tablet

4- [2 '- (4-aminophenyl) -6,6'-dibenzimidazol-2-yl] phenylamine 1

Milk sugar 103

Corn starch 25

Microcrystalline cellulose 70

Magnesium stearate _1 total 200

Example C

Capsules of the following composition are produced: mg / kg gel

2,2 ^* -dimethyl-6,6'-dibenzimidazol-2,2'-ylene-diphenol 1

Milk sugar 164 Corn starch 30

Talk _5_

Total 200

The active ingredient, milk sugar and corn starch are first mixed in a mixer and then in a shredder. You bring the mixture back into the mixer, add the talc and mix thoroughly. The mixture is filled into hard gelatin capsules by machine.

Claims

Patent claims

1. Compounds of the general formula

wherein R ¹ and R ^{2 may be the} same or different and C6H4R ³ -,

CβH3 (OH) R ⁴ - or heterocyclyl,

R ^{3 is} hydroxy, amino, lower alkoxy or cyano and

R ^{4 is} halogen, lower alkyl or lower alkoxy, and pharmaceutically acceptable salts thereof, for use as therapeutic agents, in particular as agents against bacterial pathogens.

2. Compounds according to claim 1, wherein R ¹ and R ^{2 may be the} same or different and are C6H4R ³ or CeH3 (OH) R, R ³ and R ^{4 have} the meanings given in formula I and wherein a substituent is preferably a 4- or if necessary a 3-

Occupies position on the phenyl ring.

3. 4- [2 '- (4-Hydroxyphenyl) -6,6'-dibenzimidazol-2-yl] phenol; 3- [2 '- (3-Hydroxyphenyl) -6,6'-dibenzimidazol-2-yl] phenol; 4- [2 '- (4-aminophenyl) -6,6'-dibenzimidazol-2-yl] phenylamine; 2-fluoro-4- [2 '- (3-fluoro-4-hydroxyphenyl) -6 _I 6'-dibenzimidazol-2-yl] phenol;

5- [2 '- (3-Hydroxy-4-methoxyphenyl) -6,6'-dibenzimidazol-2-yl] -2-methoxyphenol;

2,2'-bis (4-methoxyphenyl) -6,6'-dibenzimidazole;

2,2'-bis (4-ethoxyphenyl) -6,6'-dibenzimidazole;

4- [2 '- (4-ethoxyphenyl) -6,6'-dibenzimidazol-2-yl] phenol;

4- [2 '- (4-Hydroxyphenyl) -6,6'-dibenzimidazol-2-yl] benzonitrile

as compounds according to claim 1. 4. Compounds of the general formula I defined in claim 1, except

4- [2 '- (4-Hydroxyphenyl) -6,6'-dibenzimidazol-2-yl] phenol, 3- [2' - (3-Hydroxyphenyl) -6,6'-dibenzimidazol-2 -yl] phenol, 4- [2 '- (4-aminophenyl) -6,6'-dibenzimidazol-2-yl] phenylamine,

4- [2 4-Cyano-phenyl) -6,6'-dibenzimidazol-2-yl] benzonitrile

and pharmaceutically acceptable salts thereof.

5. Compounds according to claim 4, wherein R ¹ and R ^{2 may be the} same or different and C ₆ HR or CeH ₃ (OH) R ⁴ , R ³ and R ^{4 have} the meanings given in formula I and of which a substituent is preferably one 4- or optionally a 3- position on the phenyl ring.

6. 2-fluoro-4- [2 '- (3-fluoro-4-hydroxyphenyl) -6,6'-dibenzimidazol-2-yl] phenol; 4- [2 '- (4-Hydroxy-3-methoxyphenyl) -6,6'-dibenzimidazol-2-yl] -2-methoxyphenol;

2,2'-bis (4-methoxyphenyl) -6,6'-dibenzimidazole; 2,2'-bis (4-ethoxyphenyl) -6,6'-dibenzimidazole;

4- [2 '- (4-ethoxyphenyl) -6,6'-dibenzimidazol-2-yl] phenol; 4- [2 '- (4-Hydroxyphenyl) -6,6'-dibenzimidazol-2-yl] benzonitrile.

7. A process for the preparation of compounds according to claims 4-6, characterized in that

a) the compound of the formula

with an excess of a reactive compound which provides the radical R ¹ or R ² , or

b) the compound of the formula II is reacted simultaneously with two different reactive compounds which provide the radicals R ¹ and R ² , or c) a compound of the formula

wherein R ^{1 has} the meaning given in claim 1, with a reactive compound which provides the radical R ¹ or R ² , and

d) if desired, a basic compound is converted into a pharmaceutically acceptable salt by means of an acid.

8. Medicaments, in particular antibacterial agents, comprising one or more compounds of the general formula I defined in claim 1 or pharmaceutically acceptable salts thereof, and one or more therapeutically inert excipients.

9. Use of compounds of general formula I and pharmaceutically acceptable salts thereof for the production of medicinal products for the treatment of bacterial diseases, in particular infections with Staphylococcus, Enterococcus faecalis and

Helicobacter pylori.

10. Use of compounds of general formula I and pharmaceutically acceptable salts thereof in the control of diseases or the improvement of health, in particular in the prevention or treatment of bacterial diseases or for the production of corresponding medicaments.

11. Compounds according to claims 4-6, if prepared by the method according to claim 7 or an equivalent method.

12. The invention as described above.